Enhancing Diagnosis of Drug-Resistant Tuberculosis: Evaluating the Cost-Effectiveness of Rapid Molecular and Phenotypic Testing in South Africa - Summary - MDSpire
Advertisement
Enhancing Diagnosis of Drug-Resistant Tuberculosis: Evaluating the Cost-Effectiveness of Rapid Molecular and Phenotypic Testing in South Africa
To evaluate the cost-effectiveness of rapid molecular assays, alone and in combination with phenotypic drug susceptibility testing (pDST), for detecting resistance to isoniazid (INH), rifampicin (RIF), and fluoroquinolones (FQs) in TB patients in South Africa, from the perspective of healthcare providers.
Key Findings:
Only 47% of newly diagnosed TB cases in South Africa received WHO-recommended rapid molecular testing in 2023.
The treatment success rate for MDR/RR-TB was only 62%.
Rapid molecular diagnostics significantly improve the speed and accessibility of DR-TB diagnosis compared to conventional methods, reducing time to treatment initiation.
Interpretation:
The study highlights the urgent need for improved diagnostic strategies to enhance early treatment initiation and reduce mortality associated with drug-resistant tuberculosis in South Africa, emphasizing the potential impact on public health.
Limitations:
The model assumes ideal test completion rates and diagnostic yield, which may not reflect real-world scenarios, potentially skewing cost-effectiveness results.
Financial, technical, and infrastructural constraints in high-burden settings could limit the implementation of recommended testing strategies, affecting overall treatment outcomes.
Conclusion:
The evaluation underscores the potential benefits of integrating rapid molecular diagnostics with pDST to improve the management of drug-resistant tuberculosis in South Africa, highlighting the need for urgent action.
